FibroScan®
From Silent Threat to Clinical Action: Empowering Primary Care to Address Liver Disease & Improve Metabolic Outcomes
Context
|
Liver disease isn’t just a hepatology issue – it’s a critical, yet often overlooked, warning sign in primary care. In this white paper, Dr. Jinsong Zhang, a primary care physician with deep expertise in metabolic health and weight management, shares how integrating non-invasive liver screening into everyday practice improves patient outcomes, drives earlier intervention, and empowers patients to take control of their long-term health. Learn how FibroScan® is helping primary care providers bridge the liver disease diagnostic gap and make confident, real-time decisions to improve cardiometabolic health. |
 |
Key learnings
A Common Yet Overlooked Condition
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 38% of U.S. adults—and up to 70% of those with type 2 diabetes—yet often goes undetected in primary care.
Why Standard Tests Fall Short
ALT/AST and ultrasounds frequently miss early liver disease, delaying diagnosis and limiting opportunities for prevention.
Enabling Proactive Care
FibroScan® provides non-invasive, real-time liver assessment that helps primary care providers stratify risk and tailor treatment plans.
Motivating Patients Through Data
LSM by VCTE™ (an assessment of fibrosis) and CAP™ score (a measure of steatosis) help patients see their risk clearly, take action, and stay engaged in their care.
Operational & Reimbursement Benefits
FibroScan® not only enhances care, it supports GLP-1 therapy authorizations and strengthens primary care practices financially.
Download the white paper to see how primary care physician Dr. Jinsong Zhang is making liver health a cornerstone of metabolic care – and how you can, too.